{"ticker": {"uuid": "fb299ad0-2d20-40e8-ae93-dd6e5a6b24fc", "symbol": "PRQR", "name": "ProQR Therapeutics BV", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet", "summary": "ProQR Therapeutics N.V. is registering for resale up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company states it will not receive any proceeds from this offering. ProQR is a clinical-stage biotechn", "url": "https://www.stocktitan.net/sec-filings/PRQR/424b5-pro-qr-therapeutics-n-v-prospectus-supplement-debt-securities-0980ebbbbc85.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:12:53", "published_display": "15 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aescap group and Patrick Krol report ProQR (PRQR) shareholdings", "summary": "Aescap group and Patrick Krol have filed a Schedule 13G/A, disclosing their shareholdings in ProQR Therapeutics N.V. The filing indicates that Aescap Life Sciences, Aescap Genetics, Inspirational Visions, and Patrick Krol himself hold varying percentages of ProQR's ordinary share", "url": "https://www.stocktitan.net/sec-filings/PRQR/schedule-13g-a-pro-qr-therapeutics-n-v-amended-passive-investment-dis-d290f6a18eaf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T15:40:54", "published_display": "15 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNNEJfRmpXR3VUTXpFX0c3OUswczdEbk83UkIyNmxXSmNsM2Frb2Q2YTJOZVNlNlhqMlBOeHp0NXUyYzBuWjBEVXp4dFExMlRYUjRXSnZRQVhDUGN4Ym4yQ0pQcjNhZVEzbHpOMmZ3anhpSkMxWE13ckpkNi1nWXJ6RUREWFVLbFU2Nkc4WlNyNTF1VDJwdThsU0Nsb20yZDZvWE9sZHRHdGJLdjJWa28zNk9kdE11SGk3WjVuVDFVdVZHZWpjVVE?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T13:23:51+00:00", "published_display": "13 Jul 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[Form 4] ProQR Therapeutics N.V. Insider Trading Activity", "summary": "The article reports on an insider trading activity at ProQR Therapeutics N.V., where CEO Daniel Anton de Boer purchased 150,000 ordinary shares for $1.74 each on July 9, 2026, totaling $261,000. This transaction increased his direct holdings to 300,000 ordinary shares. The Form 4", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-pro-qr-therapeutics-n-v-insider-trading-activity-89a697d625e5.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:10:46", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "summary": "ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a \"Moderate Buy\" consensus recommendation from seven brokerages, with an average 12-month price target of $7.33, despite mixed individual ratings. Recent adjustments include target cuts by Chardan Capital and JonesTrading, and do", "url": "https://www.marketbeat.com/instant-alerts/proqr-therapeutics-nv-nasdaqprqr-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T06:09:48", "published_display": "10 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV", "summary": "ProQR Therapeutics NV CEO de Boer Daniel Anton recently purchased 150,000 shares of the company, increasing his total holdings to 150,000 shares. This transaction signals insider confidence, with no insider sells reported in the past year. The stock, currently trading at $1.59, a", "url": "https://www.gurufocus.com/news/8950435/insider-buying-ceo-de-boer-daniel-anton-acquires-150000-shares-of-proqr-therapeutics-nv", "source_name": "GuruFocus", "published_at": "2026-07-08T23:10:04", "published_display": "08 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59", "summary": "ProQR Therapeutics N.V. CEO Daniel Anton de Boer purchased 150,000 Ordinary Shares of the company at $1.59 per share on July 7, 2026, in an open-market transaction. This purchase established his direct ownership of 150,000 Ordinary Shares. The filing indicates a positive sentimen", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-pro-qr-therapeutics-n-v-insider-trading-activity-d1b18a8a3dfe.html", "source_name": "Stock Titan", "published_at": "2026-07-08T18:55:52", "published_display": "08 Jul 2026 18:55", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics files prospectus for 3.03M share offering", "summary": "ProQR Therapeutics has filed a prospectus for the offering of 3.03 million ordinary shares, to be sold by an existing shareholder. The company will not receive any proceeds from this sale. The offering's pricing and timing will be determined later and are subject to market condit", "url": "https://scanx.trade/stock-market-news/ipo/proqr-therapeutics-files-prospectus-for-3-03m-share-offering/44922317", "source_name": "scanx.trade", "published_at": "2026-07-07T03:10:58", "published_display": "07 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Registers Shares for Resale by Investor", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/proqr-registers-shares-resale-investor-213852728.html", "source_name": "MT Newswires", "published_at": "2026-07-06T21:38:52+00:00", "published_display": "06 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq", "summary": "ProQR Therapeutics N.V. (PRQR) has filed a Form F-3 shelf prospectus to register for resale up to 3,030,303 ordinary shares held by a selling shareholder, Ginkgo Bioworks Holdings, Inc. ProQR will not receive any proceeds from these resales, as the shares were issued to Ginkgo Ho", "url": "https://www.stocktitan.net/sec-filings/PRQR/f-3-pro-qr-therapeutics-n-v-foreign-issuer-shelf-registration-0cccd59a8bea.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:10:58", "published_display": "06 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR)", "summary": "ProQR Therapeutics (PRQR) has advanced its RNA editing platform, demonstrating human pharmacological activity with AX-0810\u2019s Phase 1 data. The company is strategically focusing on NTCP modulation for rare pediatric liver disease (biliary atresia) to achieve quicker clinical valid", "url": "https://seekingalpha.com/article/4919843-proqr-therapeutics-human-ntcp-data-strengthens-the-axiomer-thesis", "source_name": "Seeking Alpha", "published_at": "2026-07-04T15:09:59", "published_display": "04 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR posts early-stage trial data for liver disease candidate", "summary": "ProQR Therapeutics has released early-stage trial data for its investigational liver disease candidate. This initial data provides insight into the drug's performance and safety profile in its early developmental phases. Further details from the trial data were not immediately av", "url": "https://www.msn.com/en-us/health/other/proqr-posts-early-stage-trial-data-for-liver-disease-candidate/ar-AA26wsK9", "source_name": "MSN", "published_at": "2026-07-02T23:40:26", "published_display": "02 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought \u20ac231k Of Shares", "summary": "ProQR Therapeutics' Independent Non-Executive Director, Bart Filius, recently purchased US$231k worth of the company's shares at US$1.54 each. While the company recorded a loss last year, this insider buying, although at a lower price than the current US$1.75, along with past ins", "url": "https://www.sahmcapital.com/news/content/insider-buying-proqr-therapeutics-independent-non-executive-director-bought-231k-of-shares-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T19:12:13", "published_display": "02 Jul 2026 19:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRQR - ProQR Therapeutics N.V Options", "summary": "This article provides an overview of ProQR Therapeutics N.V. (PRQR) stock information as of July 2, 2026, including its last close price, daily change, and various financial metrics. It details key statistics such as market capitalization, earnings per share, sales performance, i", "url": "https://finviz.com/stock?t=PRQR&p=d&ty=oc&r=m6", "source_name": "Finviz", "published_at": "2026-07-01T18:12:09", "published_display": "01 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com", "summary": "This article announces the filing of Form 13D/A for ProQR Therapeutics N.V. for the period ending June 30th. It is a brief announcement from Investing.com, accompanied by a Reuters image and a ticker for PRQR stock performance.", "url": "https://za.investing.com/news/stock-market-news/form-13da-proqr-therapeutics-nv-for-30-june-93CH-4350792", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T17:12:09", "published_display": "01 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances", "summary": "The Van Herk group has filed an updated Schedule 13D/A, reporting a 10.9% beneficial ownership in ProQR Therapeutics N.V. (PRQR), holding 15,384,250 ordinary shares. This change in percentage is solely due to an increase in ProQR's total shares outstanding following recent issuan", "url": "https://www.stocktitan.net/sec-filings/PRQR/schedule-13d-a-pro-qr-therapeutics-n-v-amended-major-shareholder-repo-ce033361b7e9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:40:05", "published_display": "01 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ)", "summary": "This article provides financial actuals and estimates for ProQR Therapeutics N.V. (0PQ) traded on the Tradegate Exchange. It details expert forecasts including maximum and minimum price estimates, historical stock performance, and upcoming earnings report dates. The company's rec", "url": "https://www.tradingview.com/symbols/TRADEGATE-0PQ/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-07-01T05:39:32", "published_display": "01 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market", "summary": "ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares in an open-market transaction on June 26, 2026, at a price of $1.54 per share. This transaction, detailed in a Form 4 SEC filing, increases his direct holdings in ProQR to 150,000 Ordinary Shares, indi", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-pro-qr-therapeutics-n-v-insider-trading-activity-c5d84d24f2f3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:40:05", "published_display": "01 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike", "summary": "A director at ProQR Therapeutics N.V. (PRQR), Hinsch Gylvin Lykke, received a grant of 14,595 share options with an exercise price of $1.42 per share. These options, granted on June 2, 2026, will vest 25% on June 2, 2027, with the remainder vesting in quarterly installments over ", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-a-pro-qr-therapeutics-n-v-amended-insider-trading-activity-6a0912a739dc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:40:05", "published_display": "01 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0PQ Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for ProQR Therapeutics N.V. (0PQ) stock, including analyst price targets and ratings. It details quarterly and annual financial metrics such as EPS, revenue, and net income, along with historical stock performance. The piece also addresses frequen", "url": "https://www.tradingview.com/symbols/TRADEGATE-0PQ/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T20:10:52", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ProQR Therapeutics N.V. \u2013 LS:A12B97", "summary": "This article displays the \"Price to sales forward\" financial metric for ProQR Therapeutics N.V. (LS:A12B97). It indicates that for the specified period, the value is \"No trades,\" meaning no data is currently available for this metric. The article is largely a financial data stub ", "url": "https://www.tradingview.com/symbols/LS-A12B97/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:40:51", "published_display": "27 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares", "summary": "ProQR Therapeutics is conducting a public offering of 27,624,310 ordinary shares at $1.81 per share, while Eli Lilly and Company will concurrently purchase 5,100,780 shares in a private placement at the same price. The combined offerings are expected to generate approximately $55", "url": "https://www.stocktitan.net/sec-filings/PRQR/424b5-pro-qr-therapeutics-n-v-prospectus-supplement-debt-securities-4b96680cf97a.html", "source_name": "Stock Titan", "published_at": "2026-06-26T18:39:51", "published_display": "26 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success", "summary": "ProQR Therapeutics reported positive early-stage clinical data for its RNA editing therapy AX-0810, which demonstrated strong target engagement for cholestatic liver diseases. Concurrently, the company announced a $50 million underwritten offering, with Eli Lilly and Co. investin", "url": "https://www.sahmcapital.com/news/content/small-cap-proqr-therapeutics-secures-funding-from-eli-lilly-on-early-trial-success-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-26T16:41:37", "published_display": "26 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR)", "summary": "This article provides an overview of ProQR Therapeutics N.V. (NASDAQ:PRQR) stock, including its current price, performance history, and analyst forecasts. It also delves into the company's financial actuals and estimates, covering income, balance sheet, cash flow, and valuation m", "url": "https://www.tradingview.com/symbols/NASDAQ-PRQR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:06", "published_display": "26 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating", "summary": "Chardan Research has lowered its price target for ProQR Therapeutics (PRQR) to $3 from $4 but has maintained a Buy rating on the stock. This adjustment comes after the company announced positive Phase 1 target engagement data for its AX-0810 program and provided updates on its NT", "url": "https://www.marketscreener.com/news/chardan-research-adjusts-proqr-therapeutics-price-target-to-3-from-4-maintains-buy-rating-ce7f5fd9dc88ff23", "source_name": "marketscreener.com", "published_at": "2026-06-26T12:39:06", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR (PRQR) prices share offering and Eli Lilly private placement", "summary": "ProQR Therapeutics announced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $46.5 million in net proceeds. Concurrently, the company will sell 5,100,780 additional shares to Eli Lilly in a private placeme", "url": "https://www.stocktitan.net/sec-filings/PRQR/6-k-pro-qr-therapeutics-n-v-current-report-foreign-issuer-d4efcc29c2b8.html", "source_name": "Stock Titan", "published_at": "2026-06-26T09:39:51", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ProQR Therapeutics N.V. \u2013 NASDAQ:PRQR", "summary": "This article focuses on the \"Price to book forward\" metric for ProQR Therapeutics N.V. (NASDAQ: PRQR). It appears to be a stub or a section from a larger financial data platform, providing a title but no actual data or analysis other than indicating the company and the metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-PRQR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:06", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics NV - to Use Proceeds for R", "summary": "This article announces that ProQR Therapeutics NV plans to utilize the proceeds from a recent event or offering to fund its research and development initiatives.", "url": "https://www.moomoo.com/news/flash/22699886/proqr-therapeutics-nv-to-use-proceeds-for-research-clinical-development", "source_name": "Moomoo", "published_at": "2026-06-26T03:40:51", "published_display": "26 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/proqr-therapeutics-says-phase-1-112323480.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:23:23+00:00", "published_display": "25 Jun 2026 11:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/proqr-therapeutics-prices-50-million-111417574.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:14:17+00:00", "published_display": "25 Jun 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 \u2013 DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap", "summary": "The Retinitis Pigmentosa market is projected to experience significant growth by 2034, driven by increasing prevalence, awareness, and the launch of multiple pipeline products from companies like SparingVision SAS, ProQR Therapeutics NV, and Ocugen. Key developments include Ocuge", "url": "https://www.barchart.com/story/news/2647553/retinitis-pigmentosa-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2034-delveinsight-sparingvision-sas-proqr-therapeutics-nv-viridian-therapeutics-4d-molecular-therap", "source_name": "Barchart.com", "published_at": "2026-06-25T12:11:21", "published_display": "25 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR prices $50M stock offering at $1.81 per share", "summary": "ProQR Therapeutics N.V. is pricing an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $50 million. Concurrently, Eli Lilly and Company, an existing partner, will purchase an additional 5,100,780 ordinary shar", "url": "https://www.investing.com/news/company-news/proqr-prices-50m-stock-offering-at-181-per-share-93CH-4760174", "source_name": "Investing.com", "published_at": "2026-06-25T12:11:19", "published_display": "25 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/proqr-announces-positive-phase-1-102500740.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T10:25:00+00:00", "published_display": "25 Jun 2026 10:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNVjNzZTJTVUwxVFp5Tk9pU2ZfSFEtekVxRlEyMzFhMmROZl9SNEpzZzNQcUFtcG9BQkFjbW91ZXhPeGdhRXFoY0hRMzNONHJ0TnlTejNBV3AwX0hyQzZsRC1IQkNPY05nWHRmUktyQldreXVmay1yaWt1ZU8zXzZfSU1NNjdqNFI4SkNtNVRLdGs4aEV1YzhtbTBwNXhPQkdoQ2F3dzE2eXhtOUNuTFZ6Q1hCQWNlRFhaWEctRXVrZFdCQlNucThrOHpqSlQ3QUpSSGpUSU9raVdZd3lfUElFSzJ4LUM2R3V6WnZsOG1ISWk1aEsyaGhmNUZUdWhJTTJ4MVFJbA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (PRQR) Launches $50M Share Offering with Eli Lilly Participation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQV1A1UHpYb3hTRVVVZjhMWDQ1QjFKcm52LVNlLTBiNWpWUDJiMWRMd0ROSEROYXJNNVdESlVlVGF3UDBoTFhIMjJaWFNfN0M1cjlmZXRiRTc0MjFsTUkyMXJIMXp6bVoteFUzNWFDdFBuUkROeFhSb0RDa0FvazJaSzJVcWVOZ1BoVFpKdUFwSE90WVAtMGFZZy1VTTNBc1VHcDM0d2t5djVwVXFXRHNBcVV4S3JRZ1VBeWRv?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR\u2019s first RNA editing drug shows human target engagement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNWWRXUzhiMFdZSllyWHZIUzdBT2UyMU5GZkJFSDRsaVNfTXBnMUNLRVlaUEgwNGFPbm9XeER5MTUtcThhV3h4WTJIaWhiSUp0WEE5SXBiR3RWd1lOWDBTaFpZc2pBWlNwTmc0bUpuQ3BockdvOTUxMEVPQ2xWSFZjN3Nla3h4VTVsMXQtd0Y0SlBiemVFbXcyZWluNmhTQXVuZkZJU1VKZ3hGWVBZR0xQcFozVUdPVGRZXzVnOHpJdTk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. (PRQR) director awarded 14,495 stock options as compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRURyQlgwdWFhZzlkbHFBcXRfNkRmZ0xZZGlhRWZ6LV9jaTFBZW5WWU5iSjRTNE56SkpLQTFQQWdCV2lfTFZ5V05fckQ4U3NuNXhReV9IYXJrazZBLUd2QVNKZllvN3ljdHRZc2lXcmRYRWNyNUo0cEVMM0gtaDVtQWQ3bWV2UnQzU1Rka2JnamJzQkhZb2NqWE80cEZlVjdzZmtiRDlnbUtyMGZ5aXBwRXk3U19FN2Va?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/proqr-therapeutics-n-v-nasdaq-122553707.html", "source_name": "Simply Wall St.", "published_at": "2026-05-14T12:25:53+00:00", "published_display": "14 May 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ29IMnM5Slpld0QteTlqUTM1U2xLY1JQamVzRmFPTHNPQnVnR1dIbVFndVEwTzl6NmlKWjR2aHJoc0NWQ29LU2FZMzlkaGk3NllQOGM1VzdtdFh3WGFBa2w5eTVGNHRQRUl1MUlVczF2X2hGRWNYMFdmd0tPR21WNGhLdWZ0SDh1Njkyb2Z4dTVTcFNFQTlnbV9kRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYk5EY2R0NjdySGhSQUVkaDRlR0ZhQkVtVFgzVVVua0Z1MzRmSFlXNWNxbVd3Q2xiQ0pGNFpGbmdrRUpUOGZnaVpYMGhUWG55bjd2RXNnT1JhTThBb3JmcHRnUWtyODdEUmRGUUxOaVludktpeXQtSE1YOUEyZEJVRUNDeHgtMWFLRXEycUNlZC11Y2p6TFQtV0xpalNIcHpNeXJUb0NB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Growing Optimism About ProQR Therapeutics (PRQR)\u2019s RNA Editing Platform and Future Clinical Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOXVoaDVqUUdvQU1uTklEWlh4MnpQSU9tUzc2TTFKMy1RZWNhNEEzT2k1WFVhbjIxcVJ2M1NWLWV0b2VIelNFY2gxbmh3UG1TbVdJcmVEeThONmhDQTBHU3hRQzV6OGpsTXhhTmdQbEx0cHNCNHVCTkVKdE4zVml0WkNWSUt1aEg5Slg3S0Z6N2tiMWtORWtFWGpUaFpHUXBsbWhhNW1FWEY?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet", "summary": "ProQR Therapeutics N.V. is registering for resale up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company states it will not receive any proceeds from this offering. ProQR is a clinical-stage biotechn", "url": "https://www.stocktitan.net/sec-filings/PRQR/424b5-pro-qr-therapeutics-n-v-prospectus-supplement-debt-securities-0980ebbbbc85.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:12:53", "published_display": "15 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aescap group and Patrick Krol report ProQR (PRQR) shareholdings", "summary": "Aescap group and Patrick Krol have filed a Schedule 13G/A, disclosing their shareholdings in ProQR Therapeutics N.V. The filing indicates that Aescap Life Sciences, Aescap Genetics, Inspirational Visions, and Patrick Krol himself hold varying percentages of ProQR's ordinary share", "url": "https://www.stocktitan.net/sec-filings/PRQR/schedule-13g-a-pro-qr-therapeutics-n-v-amended-passive-investment-dis-d290f6a18eaf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T15:40:54", "published_display": "15 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNNEJfRmpXR3VUTXpFX0c3OUswczdEbk83UkIyNmxXSmNsM2Frb2Q2YTJOZVNlNlhqMlBOeHp0NXUyYzBuWjBEVXp4dFExMlRYUjRXSnZRQVhDUGN4Ym4yQ0pQcjNhZVEzbHpOMmZ3anhpSkMxWE13ckpkNi1nWXJ6RUREWFVLbFU2Nkc4WlNyNTF1VDJwdThsU0Nsb20yZDZvWE9sZHRHdGJLdjJWa28zNk9kdE11SGk3WjVuVDFVdVZHZWpjVVE?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T13:23:51+00:00", "published_display": "13 Jul 2026 13:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] ProQR Therapeutics N.V. Insider Trading Activity", "summary": "The article reports on an insider trading activity at ProQR Therapeutics N.V., where CEO Daniel Anton de Boer purchased 150,000 ordinary shares for $1.74 each on July 9, 2026, totaling $261,000. This transaction increased his direct holdings to 300,000 ordinary shares. The Form 4", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-pro-qr-therapeutics-n-v-insider-trading-activity-89a697d625e5.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:10:46", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "summary": "ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a \"Moderate Buy\" consensus recommendation from seven brokerages, with an average 12-month price target of $7.33, despite mixed individual ratings. Recent adjustments include target cuts by Chardan Capital and JonesTrading, and do", "url": "https://www.marketbeat.com/instant-alerts/proqr-therapeutics-nv-nasdaqprqr-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T06:09:48", "published_display": "10 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV", "summary": "ProQR Therapeutics NV CEO de Boer Daniel Anton recently purchased 150,000 shares of the company, increasing his total holdings to 150,000 shares. This transaction signals insider confidence, with no insider sells reported in the past year. The stock, currently trading at $1.59, a", "url": "https://www.gurufocus.com/news/8950435/insider-buying-ceo-de-boer-daniel-anton-acquires-150000-shares-of-proqr-therapeutics-nv", "source_name": "GuruFocus", "published_at": "2026-07-08T23:10:04", "published_display": "08 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59", "summary": "ProQR Therapeutics N.V. CEO Daniel Anton de Boer purchased 150,000 Ordinary Shares of the company at $1.59 per share on July 7, 2026, in an open-market transaction. This purchase established his direct ownership of 150,000 Ordinary Shares. The filing indicates a positive sentimen", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-pro-qr-therapeutics-n-v-insider-trading-activity-d1b18a8a3dfe.html", "source_name": "Stock Titan", "published_at": "2026-07-08T18:55:52", "published_display": "08 Jul 2026 18:55", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics files prospectus for 3.03M share offering", "summary": "ProQR Therapeutics has filed a prospectus for the offering of 3.03 million ordinary shares, to be sold by an existing shareholder. The company will not receive any proceeds from this sale. The offering's pricing and timing will be determined later and are subject to market condit", "url": "https://scanx.trade/stock-market-news/ipo/proqr-therapeutics-files-prospectus-for-3-03m-share-offering/44922317", "source_name": "scanx.trade", "published_at": "2026-07-07T03:10:58", "published_display": "07 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Registers Shares for Resale by Investor", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/proqr-registers-shares-resale-investor-213852728.html", "source_name": "MT Newswires", "published_at": "2026-07-06T21:38:52+00:00", "published_display": "06 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq", "summary": "ProQR Therapeutics N.V. (PRQR) has filed a Form F-3 shelf prospectus to register for resale up to 3,030,303 ordinary shares held by a selling shareholder, Ginkgo Bioworks Holdings, Inc. ProQR will not receive any proceeds from these resales, as the shares were issued to Ginkgo Ho", "url": "https://www.stocktitan.net/sec-filings/PRQR/f-3-pro-qr-therapeutics-n-v-foreign-issuer-shelf-registration-0cccd59a8bea.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:10:58", "published_display": "06 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR)", "summary": "ProQR Therapeutics (PRQR) has advanced its RNA editing platform, demonstrating human pharmacological activity with AX-0810\u2019s Phase 1 data. The company is strategically focusing on NTCP modulation for rare pediatric liver disease (biliary atresia) to achieve quicker clinical valid", "url": "https://seekingalpha.com/article/4919843-proqr-therapeutics-human-ntcp-data-strengthens-the-axiomer-thesis", "source_name": "Seeking Alpha", "published_at": "2026-07-04T15:09:59", "published_display": "04 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR posts early-stage trial data for liver disease candidate", "summary": "ProQR Therapeutics has released early-stage trial data for its investigational liver disease candidate. This initial data provides insight into the drug's performance and safety profile in its early developmental phases. Further details from the trial data were not immediately av", "url": "https://www.msn.com/en-us/health/other/proqr-posts-early-stage-trial-data-for-liver-disease-candidate/ar-AA26wsK9", "source_name": "MSN", "published_at": "2026-07-02T23:40:26", "published_display": "02 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought \u20ac231k Of Shares", "summary": "ProQR Therapeutics' Independent Non-Executive Director, Bart Filius, recently purchased US$231k worth of the company's shares at US$1.54 each. While the company recorded a loss last year, this insider buying, although at a lower price than the current US$1.75, along with past ins", "url": "https://www.sahmcapital.com/news/content/insider-buying-proqr-therapeutics-independent-non-executive-director-bought-231k-of-shares-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T19:12:13", "published_display": "02 Jul 2026 19:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRQR - ProQR Therapeutics N.V Options", "summary": "This article provides an overview of ProQR Therapeutics N.V. (PRQR) stock information as of July 2, 2026, including its last close price, daily change, and various financial metrics. It details key statistics such as market capitalization, earnings per share, sales performance, i", "url": "https://finviz.com/stock?t=PRQR&p=d&ty=oc&r=m6", "source_name": "Finviz", "published_at": "2026-07-01T18:12:09", "published_display": "01 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com", "summary": "This article announces the filing of Form 13D/A for ProQR Therapeutics N.V. for the period ending June 30th. It is a brief announcement from Investing.com, accompanied by a Reuters image and a ticker for PRQR stock performance.", "url": "https://za.investing.com/news/stock-market-news/form-13da-proqr-therapeutics-nv-for-30-june-93CH-4350792", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T17:12:09", "published_display": "01 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances", "summary": "The Van Herk group has filed an updated Schedule 13D/A, reporting a 10.9% beneficial ownership in ProQR Therapeutics N.V. (PRQR), holding 15,384,250 ordinary shares. This change in percentage is solely due to an increase in ProQR's total shares outstanding following recent issuan", "url": "https://www.stocktitan.net/sec-filings/PRQR/schedule-13d-a-pro-qr-therapeutics-n-v-amended-major-shareholder-repo-ce033361b7e9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:40:05", "published_display": "01 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ)", "summary": "This article provides financial actuals and estimates for ProQR Therapeutics N.V. (0PQ) traded on the Tradegate Exchange. It details expert forecasts including maximum and minimum price estimates, historical stock performance, and upcoming earnings report dates. The company's rec", "url": "https://www.tradingview.com/symbols/TRADEGATE-0PQ/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-07-01T05:39:32", "published_display": "01 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market", "summary": "ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares in an open-market transaction on June 26, 2026, at a price of $1.54 per share. This transaction, detailed in a Form 4 SEC filing, increases his direct holdings in ProQR to 150,000 Ordinary Shares, indi", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-pro-qr-therapeutics-n-v-insider-trading-activity-c5d84d24f2f3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:40:05", "published_display": "01 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike", "summary": "A director at ProQR Therapeutics N.V. (PRQR), Hinsch Gylvin Lykke, received a grant of 14,595 share options with an exercise price of $1.42 per share. These options, granted on June 2, 2026, will vest 25% on June 2, 2027, with the remainder vesting in quarterly installments over ", "url": "https://www.stocktitan.net/sec-filings/PRQR/form-4-a-pro-qr-therapeutics-n-v-amended-insider-trading-activity-6a0912a739dc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:40:05", "published_display": "01 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0PQ Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for ProQR Therapeutics N.V. (0PQ) stock, including analyst price targets and ratings. It details quarterly and annual financial metrics such as EPS, revenue, and net income, along with historical stock performance. The piece also addresses frequen", "url": "https://www.tradingview.com/symbols/TRADEGATE-0PQ/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T20:10:52", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ProQR Therapeutics N.V. \u2013 LS:A12B97", "summary": "This article displays the \"Price to sales forward\" financial metric for ProQR Therapeutics N.V. (LS:A12B97). It indicates that for the specified period, the value is \"No trades,\" meaning no data is currently available for this metric. The article is largely a financial data stub ", "url": "https://www.tradingview.com/symbols/LS-A12B97/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:40:51", "published_display": "27 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares", "summary": "ProQR Therapeutics is conducting a public offering of 27,624,310 ordinary shares at $1.81 per share, while Eli Lilly and Company will concurrently purchase 5,100,780 shares in a private placement at the same price. The combined offerings are expected to generate approximately $55", "url": "https://www.stocktitan.net/sec-filings/PRQR/424b5-pro-qr-therapeutics-n-v-prospectus-supplement-debt-securities-4b96680cf97a.html", "source_name": "Stock Titan", "published_at": "2026-06-26T18:39:51", "published_display": "26 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success", "summary": "ProQR Therapeutics reported positive early-stage clinical data for its RNA editing therapy AX-0810, which demonstrated strong target engagement for cholestatic liver diseases. Concurrently, the company announced a $50 million underwritten offering, with Eli Lilly and Co. investin", "url": "https://www.sahmcapital.com/news/content/small-cap-proqr-therapeutics-secures-funding-from-eli-lilly-on-early-trial-success-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-26T16:41:37", "published_display": "26 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR)", "summary": "This article provides an overview of ProQR Therapeutics N.V. (NASDAQ:PRQR) stock, including its current price, performance history, and analyst forecasts. It also delves into the company's financial actuals and estimates, covering income, balance sheet, cash flow, and valuation m", "url": "https://www.tradingview.com/symbols/NASDAQ-PRQR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:06", "published_display": "26 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating", "summary": "Chardan Research has lowered its price target for ProQR Therapeutics (PRQR) to $3 from $4 but has maintained a Buy rating on the stock. This adjustment comes after the company announced positive Phase 1 target engagement data for its AX-0810 program and provided updates on its NT", "url": "https://www.marketscreener.com/news/chardan-research-adjusts-proqr-therapeutics-price-target-to-3-from-4-maintains-buy-rating-ce7f5fd9dc88ff23", "source_name": "marketscreener.com", "published_at": "2026-06-26T12:39:06", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR (PRQR) prices share offering and Eli Lilly private placement", "summary": "ProQR Therapeutics announced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $46.5 million in net proceeds. Concurrently, the company will sell 5,100,780 additional shares to Eli Lilly in a private placeme", "url": "https://www.stocktitan.net/sec-filings/PRQR/6-k-pro-qr-therapeutics-n-v-current-report-foreign-issuer-d4efcc29c2b8.html", "source_name": "Stock Titan", "published_at": "2026-06-26T09:39:51", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of ProQR Therapeutics N.V. \u2013 NASDAQ:PRQR", "summary": "This article focuses on the \"Price to book forward\" metric for ProQR Therapeutics N.V. (NASDAQ: PRQR). It appears to be a stub or a section from a larger financial data platform, providing a title but no actual data or analysis other than indicating the company and the metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-PRQR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:06", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics NV - to Use Proceeds for R", "summary": "This article announces that ProQR Therapeutics NV plans to utilize the proceeds from a recent event or offering to fund its research and development initiatives.", "url": "https://www.moomoo.com/news/flash/22699886/proqr-therapeutics-nv-to-use-proceeds-for-research-clinical-development", "source_name": "Moomoo", "published_at": "2026-06-26T03:40:51", "published_display": "26 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/proqr-therapeutics-says-phase-1-112323480.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:23:23+00:00", "published_display": "25 Jun 2026 11:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/proqr-therapeutics-prices-50-million-111417574.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:14:17+00:00", "published_display": "25 Jun 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 \u2013 DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap", "summary": "The Retinitis Pigmentosa market is projected to experience significant growth by 2034, driven by increasing prevalence, awareness, and the launch of multiple pipeline products from companies like SparingVision SAS, ProQR Therapeutics NV, and Ocugen. Key developments include Ocuge", "url": "https://www.barchart.com/story/news/2647553/retinitis-pigmentosa-market-unlocking-new-revenue-opportunities-and-strategic-expansion-by-2034-delveinsight-sparingvision-sas-proqr-therapeutics-nv-viridian-therapeutics-4d-molecular-therap", "source_name": "Barchart.com", "published_at": "2026-06-25T12:11:21", "published_display": "25 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR prices $50M stock offering at $1.81 per share", "summary": "ProQR Therapeutics N.V. is pricing an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $50 million. Concurrently, Eli Lilly and Company, an existing partner, will purchase an additional 5,100,780 ordinary shar", "url": "https://www.investing.com/news/company-news/proqr-prices-50m-stock-offering-at-181-per-share-93CH-4760174", "source_name": "Investing.com", "published_at": "2026-06-25T12:11:19", "published_display": "25 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/proqr-announces-positive-phase-1-102500740.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T10:25:00+00:00", "published_display": "25 Jun 2026 10:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNVjNzZTJTVUwxVFp5Tk9pU2ZfSFEtekVxRlEyMzFhMmROZl9SNEpzZzNQcUFtcG9BQkFjbW91ZXhPeGdhRXFoY0hRMzNONHJ0TnlTejNBV3AwX0hyQzZsRC1IQkNPY05nWHRmUktyQldreXVmay1yaWt1ZU8zXzZfSU1NNjdqNFI4SkNtNVRLdGs4aEV1YzhtbTBwNXhPQkdoQ2F3dzE2eXhtOUNuTFZ6Q1hCQWNlRFhaWEctRXVrZFdCQlNucThrOHpqSlQ3QUpSSGpUSU9raVdZd3lfUElFSzJ4LUM2R3V6WnZsOG1ISWk1aEsyaGhmNUZUdWhJTTJ4MVFJbA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics (PRQR) Launches $50M Share Offering with Eli Lilly Participation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQV1A1UHpYb3hTRVVVZjhMWDQ1QjFKcm52LVNlLTBiNWpWUDJiMWRMd0ROSEROYXJNNVdESlVlVGF3UDBoTFhIMjJaWFNfN0M1cjlmZXRiRTc0MjFsTUkyMXJIMXp6bVoteFUzNWFDdFBuUkROeFhSb0RDa0FvazJaSzJVcWVOZ1BoVFpKdUFwSE90WVAtMGFZZy1VTTNBc1VHcDM0d2t5djVwVXFXRHNBcVV4S3JRZ1VBeWRv?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR\u2019s first RNA editing drug shows human target engagement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNWWRXUzhiMFdZSllyWHZIUzdBT2UyMU5GZkJFSDRsaVNfTXBnMUNLRVlaUEgwNGFPbm9XeER5MTUtcThhV3h4WTJIaWhiSUp0WEE5SXBiR3RWd1lOWDBTaFpZc2pBWlNwTmc0bUpuQ3BockdvOTUxMEVPQ2xWSFZjN3Nla3h4VTVsMXQtd0Y0SlBiemVFbXcyZWluNmhTQXVuZkZJU1VKZ3hGWVBZR0xQcFozVUdPVGRZXzVnOHpJdTk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. (PRQR) director awarded 14,495 stock options as compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRURyQlgwdWFhZzlkbHFBcXRfNkRmZ0xZZGlhRWZ6LV9jaTFBZW5WWU5iSjRTNE56SkpLQTFQQWdCV2lfTFZ5V05fckQ4U3NuNXhReV9IYXJrazZBLUd2QVNKZllvN3ljdHRZc2lXcmRYRWNyNUo0cEVMM0gtaDVtQWQ3bWV2UnQzU1Rka2JnamJzQkhZb2NqWE80cEZlVjdzZmtiRDlnbUtyMGZ5aXBwRXk3U19FN2Va?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/proqr-therapeutics-n-v-nasdaq-122553707.html", "source_name": "Simply Wall St.", "published_at": "2026-05-14T12:25:53+00:00", "published_display": "14 May 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZ29IMnM5Slpld0QteTlqUTM1U2xLY1JQamVzRmFPTHNPQnVnR1dIbVFndVEwTzl6NmlKWjR2aHJoc0NWQ29LU2FZMzlkaGk3NllQOGM1VzdtdFh3WGFBa2w5eTVGNHRQRUl1MUlVczF2X2hGRWNYMFdmd0tPR21WNGhLdWZ0SDh1Njkyb2Z4dTVTcFNFQTlnbV9kRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYk5EY2R0NjdySGhSQUVkaDRlR0ZhQkVtVFgzVVVua0Z1MzRmSFlXNWNxbVd3Q2xiQ0pGNFpGbmdrRUpUOGZnaVpYMGhUWG55bjd2RXNnT1JhTThBb3JmcHRnUWtyODdEUmRGUUxOaVludktpeXQtSE1YOUEyZEJVRUNDeHgtMWFLRXEycUNlZC11Y2p6TFQtV0xpalNIcHpNeXJUb0NB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Growing Optimism About ProQR Therapeutics (PRQR)\u2019s RNA Editing Platform and Future Clinical Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOXVoaDVqUUdvQU1uTklEWlh4MnpQSU9tUzc2TTFKMy1RZWNhNEEzT2k1WFVhbjIxcVJ2M1NWLWV0b2VIelNFY2gxbmh3UG1TbVdJcmVEeThONmhDQTBHU3hRQzV6OGpsTXhhTmdQbEx0cHNCNHVCTkVKdE4zVml0WkNWSUt1aEg5Slg3S0Z6N2tiMWtORWtFWGpUaFpHUXBsbWhhNW1FWEY?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 49, "sentiment_summary": {"positive": 12, "negative": 3, "neutral": 34, "score": 55, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.55, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.73, "latest_week": "2026-07-10", "one_week_move": -4.4, "four_week_move": 20.1, "twelve_week_move": -13.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.053448, "market_dynamics_buy_signal": false, "relative_strength": -24.459449, "fair_value_gap": -13.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.973, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.4% over one week, +20.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "MT Newswires", "count": 3}, {"label": "MarketBeat", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.4% over one week, +20.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet"}], "updated_at": "2026-07-16T08:10:42.820772+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}